» Articles » PMID: 32258944

Pathogenesis of Nonalcoholic Steatohepatitis: An Overview

Overview
Journal Hepatol Commun
Specialty Gastroenterology
Date 2020 Apr 8
PMID 32258944
Citations 178
Authors
Affiliations
Soon will be listed here.
Abstract

Nonalcoholic fatty liver disease (NAFLD) is a heterogeneous group of liver diseases characterized by the accumulation of fat in the liver. The heterogeneity of NAFLD is reflected in a clinical and histologic spectrum where some patients develop isolated steatosis of the liver, termed nonalcoholic fatty liver, whereas others develop hepatocyte injury, ballooning, inflammation, and consequent fibrosis, termed nonalcoholic steatohepatitis (NASH). Systemic insulin resistance is a major driver of hepatic steatosis in NAFLD. Lipotoxicity of accumulated lipids along with activation of the innate immune system are major drivers of NASH. Lipid-induced sublethal and lethal stress culminates in the activation of inflammatory processes, such as the release of proinflammatory extracellular vesicles and cell death. Innate and adaptive immune mechanisms involving macrophages, dendritic cells, and lymphocytes are central drivers of inflammation that recognize damage- and pathogen-associated molecular patterns and contribute to the progression of the inflammatory cascade. While the activation of the innate immune system and the recruitment of proinflammatory monocytes into the liver in NASH are well known, the exact signals that lead to this remain less well defined. Further, the contribution of other immune cell types, such as neutrophils and B cells, is an area of intense research. Many host factors, such as the microbiome and gut-liver axis, modify individual susceptibility to NASH. In this review, we discuss lipotoxicity, inflammation, and the contribution of interorgan crosstalk in NASH pathogenesis.

Citing Articles

Metabolic dysfunction-associated steatotic liver disease in adults.

Huang D, Wong V, Rinella M, Boursier J, Lazarus J, Yki-Jarvinen H Nat Rev Dis Primers. 2025; 11(1):14.

PMID: 40050362 DOI: 10.1038/s41572-025-00599-1.


Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis.

Devasia A, Ramasamy A, Leo C Int J Mol Sci. 2025; 26(4).

PMID: 40004240 PMC: 11855529. DOI: 10.3390/ijms26041778.


From Pathophysiology to Practice: Evolving Pharmacological Therapies, Clinical Complications, and Pharmacogenetic Considerations in Portal Hypertension.

Porada M, Buldak L Metabolites. 2025; 15(2).

PMID: 39997697 PMC: 11857179. DOI: 10.3390/metabo15020072.


Identification and Validation of Biomarkers in Metabolic Dysfunction-Associated Steatohepatitis Using Machine Learning and Bioinformatics.

Zhang Y, Li J, Zeng H, Liu S, Luo Y, Yu P Mol Genet Genomic Med. 2025; 13(2):e70063.

PMID: 39995143 PMC: 11850758. DOI: 10.1002/mgg3.70063.


Advanced lung cancer inflammation index: a key predictor of hepatic steatosis and fibrosis severity.

Liu Y, Wang R BMC Gastroenterol. 2025; 25(1):106.

PMID: 39994578 PMC: 11849289. DOI: 10.1186/s12876-024-03544-w.


References
1.
Mehal W . The inflammasome in liver injury and non-alcoholic fatty liver disease. Dig Dis. 2014; 32(5):507-15. DOI: 10.1159/000360495. View

2.
Samuel V, Shulman G . The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest. 2016; 126(1):12-22. PMC: 4701542. DOI: 10.1172/JCI77812. View

3.
Schuster J, Nelson P . Toll receptors: an expanding role in our understanding of human disease. J Leukoc Biol. 2000; 67(6):767-73. View

4.
Winer D, Winer S, Shen L, Wadia P, Yantha J, Paltser G . B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat Med. 2011; 17(5):610-7. PMC: 3270885. DOI: 10.1038/nm.2353. View

5.
Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal W, Strowig T . Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012; 482(7384):179-85. PMC: 3276682. DOI: 10.1038/nature10809. View